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SUMMARY (150 max) 
Endosomal Sorting Complex Required for Transport (ESCRT) complex proteins regulate 
biogenesis and release of extracellular vesicles (EVs), which enable cell-to-cell communication 
in the nervous system that is essential for development and adult function. We recently showed 
human loss of function (LOF) mutations in the ESCRT-III member CHMP1A cause autosomal 
recessive microcephaly with pontocerebellar hypoplasia (Mochida et al., 2012). Here, we show 
Chmp1a is required for progenitor proliferation in mouse cortex and cerebellum, and progenitor 
maintenance in human cerebral organoids. CHMP1A regulates proliferation through Sonic 
hedgehog (SHH) secretion. Loss of CHMP1A reduces intraluminal vesicle (ILV) formation in 
multivesicular bodies (MVBs) and EV release, and SHH protein is present on ART-EVs, a new 
EV subtype marked by a unique set of proteins. CHMP1A loss specifically impairs secretion of 
SHH on ART-EVs. CHMP1A’s requirement in the formation of ART-EVs and other EVs 
provides a model to elucidate EV functions in multiple brain processes. 
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INTRODUCTION 
EVs are increasingly recognized as essential mediators of specialized cellular secretion, 
but the mechanisms of EV function are not well understood, in part because of the diversity of 
EV classes (Bobrie et al., 2012, Kowal et al., 2016) and the lack of tools to specifically disrupt 
individual EV classes. EVs are essential for cell-to-cell communication by allowing hydrophobic 
signaling molecules (Korkut et al., 2009), RNA (Tietje et al., 2014), and other specialized cargo 
(Budnik et al., 2016) to travel through an aqueous extracellular environment. At Drosophila 
neuromuscular junction, EV-mediated wingless secretion is required for synapse growth, and 
EV-mediated Synaptotagmin 4 secretion is required for retrograde signaling (Koles et al., 2012; 
Korkut et al., 2009; Korkut et al., 2013). Cultured mammalian neurons (Lachenal et al., 2011), 
oligodendrocytes (Fruhbeis et al., 2013), and microglia (Antonucci et al., 2012) secrete EVs that 
have been proposed to modulate synaptic strength and cell viability analogously, and perhaps 
even to mediate pathological transfer of RNAs, prion-like proteins, and Tau proteins (Asai et al., 
2015). However, these functions remains somewhat speculative because of a lack of in vivo 
vertebrate models that selectively disrupt EV function.  
Shh is a hydrophobic secreted factor essential for embryonic development, serving as a 
morphogen (Cohen et al., 2015; Roelink et al., 1995), a mitogen (Nielsen and Dymecki, 2010; 
Dahmane and Ruiz i Altaba, 1999), an axon guidance molecule (Wilson and Stoeckli, 2013; 
Charron et al., 2003), and a regulator of synapse formation (Harwell et al., 2012). In developing 
cerebellum, Shh stimulates proliferation of precursors that generate granule neurons (GCPs), the 
most abundant neuron in brain (Zhou et al., 2007), and loss of Shh causes profound cerebellar 
hypoplasia (Corrales et al., 2006). Whereas the source of secreted Shh that regulates GCP 
proliferation is Purkinje cells (PC) (Wechsler-Reya and Scott, 1999), the mechanism of Shh 
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secretion is unclear because studies have reported multiple different secretion mechanisms 
including oligomeric complexes (Zeng et al., 2001), lipoprotein particles (Panakova et al., 2005), 
and exovesicles (Matusek et al., 2014), including exosomes (Vyas et al., 2014). 
ESCRT machinery regulates EV formation and release as well as other membrane 
remodeling processes in the cell. ESCRT members are grouped into four subunits (0 to III) that 
drive different steps in membrane remodeling including deformation, budding, and scission 
(McCullough et al., 2013). The ESCRT-III complex comprises eleven subunits designated 
CHMPs (Charged Multivesicular Body Proteins) particularly important for membrane scission. 
Several conflicting potential mechanisms have been proposed to explain why LOF mutations in 
an ESCRT-III member, CHMP1A, cause microcephaly with pontocerebellar hypoplasia and 
short stature in humans (Mochida et al., 2012, Howard et al., 2001). Here, we show that, 
analogous to Drosophila (Matusek et al., 2014), CHMP1A is an essential mediator of vertebrate 
SHH secretion during brain development. Chmp1a null mice show widespread defects in 
forebrain and hindbrain development with evidence of disrupted Shh signaling, which can be 
rescued by activation of downstream signaling. Further, Shh protein level in the cerebrospinal 
fluid (CSF) of Chmp1a null embryos is markedly reduced compared to littermate controls. 
Chmp1a is specifically required for vesicular SHH secretion. Chmp1a loss impairs EV 
biogenesis by reducing ILVs within MVBs and disrupts secretion of a unique SHH-positive EV 
subtype we call ART-EVs as well as exosomes. CHMP1A function reveals an unexpected 
diversity and specificity of EV subtypes, and provides an essential vertebrate model to dissect 
EV function. 
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RESULTS 
Chmp1a is required for embryonic development 
We created a Chmp1a gene trap (GT) mouse line as shown in Figure S1 that completely 
removes Chmp1a protein. A gene trap cassette (Stryke et al., 2003) inserted in intron 1 of 
Chmp1a contains a strong splice acceptor from En2 fused to the coding sequence for beta-
galactosidase (Figure S1A). ES cells containing this GT allele were injected into mouse 
blastocysts to generate Chmp1a GT chimeras, which were outcrossed to create germline Chmp1a 
GT allele carriers. DNA sequencing confirms that in homozygous GT embryos, Chmp1a intron 1 
is fused to En intron 1 (Figure S1C). Heterozygous GT mice show reduced Chmp1a protein 
expression compared to wild type (WT) and homozygous GT mice express no detectable 
Chmp1a protein (Figure S1B), confirming a null mutation. 
Chmp1a is required for normal embryonic development and postnatal survival in mice, 
with Chmp1a null embryos being significantly smaller than littermate controls during 
embryogenesis and 40% smaller than controls at birth (two-tailed t-test, p = 2x10-5; Figures 1A, 
1C). Chmp1a null mice die at or soon after birth (Figure S1D), with brains that are 14% smaller 
than controls (two-tailed t-test, p = 0.01, Figures 1B, 1D), while Chmp1a heterozygous mice are 
indistinguishable from wild type controls, and hence are combined with WT in all analyses 
(Figures S1E, S1F). Chmp1a null mice have smaller olfactory bulbs, a smaller and thinner 
cerebral cortex, smaller striatum, and a smaller cerebellum with reduced foliation (Figures 1E-
H, S1G). Together, reduced body size, microcephaly, reduced basal ganglia, and cerebellar 
hypoplasia in Chmp1a null mice closely models the phenotype of CHMP1A null patients 
(Mochida et al., 2012; Figure S2). 
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Chmp1a is expressed in post-mitotic neurons and choroid plexus during brain development 
 Insertion of lacZ into the Chmp1a locus provided crucial information about normal 
expression that suggested potential mechanisms. Heterozygous GT mice show expression of 
Chmp1a-lacZ in developing cerebellum and hindbrain choroid plexus (ChP) (Figures 2A, S3C). 
At postnatal day (P) 4, the peak of GCP proliferation, Chmp1a-lacZ is specifically expressed in 
PC layer (Figure 2A) and is undetectable in GCPs. Immunofluorescence confirmed the 
localization of Chmp1a protein in ChP and in PCs in the developing cerebellum with little 
expression in GCPs of the external granule layer (EGL) (Figures 2B, S3D). RNAscope in 
developing human cerebellum (gestational week (GW) 20) confirmed CHMP1A expression in 
the PC layer, identified as the cell layer expressing SHH and superficial to PTCH positive 
internal granule layer (Figure 2C), and further showed that SHH, CHMP1A, and CD63 are 
expressed in the same cell population, suggesting co-expression in PCs (Figure 2D). 
Immunostaining showed Chmp1a expression in AQP1-positive choroid plexus epithelial cells 
(Figure S3A), confirming RNA-sequencing from purified epithelial cells (Lun et al., 2015a). In 
developing mouse cerebral cortex, Chmp1a immunoreactivity is enriched in post-mitotic neurons 
of the cortical plate compared to ventricular zone progenitors (Figure 2E), and RNAscope in 
developing human cortex (GW20) confirmed CHMP1A expression in the cortical plate along 
with CD63, whereas the downstream SHH target PTCH is expressed in a complementary fashion 
in dividing progenitors of the ventricular zone (Figures 2F, S3B). The similar expression 
patterns of SHH, CD63, and CHMP1A in postmitotic neurons, with the complementary 
expression of PTCH in progenitors, suggest non cell-autonomous roles for CHMP1A in 
proliferation via regulation of one or more secreted factors, such as SHH. 
 
 8 
Chmp1a is essential for neuroprogenitor proliferation 
Chmp1a null mouse embryos show defects in progenitor proliferation in cerebellum, 
cortex, and basal ganglia (Figure 3). At P0, the latest age we can study due to lethality, GCP 
proliferation in the developing cerebellum is significantly impaired in Chmp1a null mice with 
40% fewer mitotic GCPs than littermate controls (labeled with phosphorylated histone H3 (pH3), 
two-tailed t-test, p = 0.0001; Figure 3A). This deficit is twice as large as the reduction in mitotic 
progenitors in the developing cortex and matches human CHMP1A null patients, whose 
cerebellar hypoplasia is strikingly severe in relation to more modest microcephaly (Mochida et 
al., 2012; Figure S2). The overall size of the cerebellum is already reduced at P0 in Chmp1a null 
mice (Figure 1G), with a 20% reduction in mitotic GCP density compared to controls (two-
tailed t-test, p = 0.0009; Figure 3A), whereas PCs are not detectably affected in mutant mice 
(cerebellum area: 36% vs 33%, two-tailed t-test, p = 0.16; Figures S4A, S4B), 
Chmp1a null embryos have decreased anterior to posterior cerebral cortex length (Figure 
1B), a 13% thinner cortex (two-tailed t-test, p = 0.03), and defects in cortical layers (Figure 1E); 
all suggesting defects in cortical neurogenesis. Superficial cortical layers (II-IV, Cux1 positive 
neurons) are reduced by 25% in the mutants (two-tailed t-test, p = 0.002), while deep cortical 
layers (V-VI, Ctip2 positive neurons) are less affected (9% reduction, two-tailed t-test, p = 0.08; 
Figure 1E). Preferential reduction of upper cortical layers commonly reflects defects of cortical 
neurogenesis (Lizarraga et al., 2010), since cortical layers form in an inside-out sequence, with 
deep-layer neurons born first and upper-layer neurons born last (Greig et al., 2013). 
Quantification of mitotic ventricular zone progenitors at embryonic day (E) 14.5 showed 20% 
fewer mitotic ventricular zone progenitors in mutants compared to controls (two-tailed t-test, p = 
0.003; Figure 3B) and, at E13.5, mutant embryos had 26% fewer Tbr2 positive intermediate 
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progenitors than controls (two-tailed t-test, p = 0.035, Figure 3C). Chmp1a null embryos had no 
detectable increase in cleaved caspase-3 positive apoptotic cells (Figures S4C, S4D) and intact 
epithelial structure with normal localization of key proteins such as aPKC and beta-catenin 
(Figure S4E), suggesting that the microcephaly and cortical thinning result from decreased 
progenitor proliferation. Mutant embryos also showed normal progression of cytokinesis in 
cortical progenitors measured by the ratio of pH3-positive early mitotic cells to aurora A-positive 
cells undergoing abscission (Figures S5A, B) and normal DNA content measured by Propidium 
iodide staining of embryonic fibroblasts (MEFs) (Figure S5D). These data suggest loss of 
Chmp1a causes defects in proliferation, but not cytokinesis, a process in which the ESCRT 
complex has also been implicated (Carlton et al., 2012). 
In late-embryonic ventral telencephalon, the striatum is 25% smaller in the absence of 
Chmp1a (two-tailed t-test, p = 0.0004; Figure 1F), which results from decreased progenitor 
proliferation at E12.5 in MGE and LGE. Immunostaining for pH3 during MGE and LGE 
neurogenesis (E12.5) shows a dramatic 43% reduction in pH3 positive progenitors in Chmp1a 
null embryos (two-tailed t-test, p = 0.016; Figure 3D), revealing essential roles for Chmp1a in 
ventral telencephalon that are also seen in humans with CHMP1A mutations (Figure S2). 
 
Chmp1a is essential for Shh-mediated progenitor proliferation 
Since Shh is the primary mitogen that drives GCP proliferation (Corrales et al., 2004; 
Dahmane and Ruiz i Altaba, 1999), the reduced GCP proliferation in Chmp1a null mice 
prompted examination of whether Chmp1a is required for Shh-mediated proliferation. In control 
mice at birth, Shh signaling is more active anteriorly than dorsally in the cerebellum (Corrales et 
al., 2004), with almost twice the number of mitotic GCPs (pH3+) in anterior EGL compared to 
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dorsal EGL. In Chmp1a null mice, this difference was substantially reduced to 1.25-fold (two-
tailed t-test, p = 0.005; Figures S4F, S4G) consistent with defective Shh signaling. In situ 
hybridization for Ptch, a downstream target of Shh signaling, revealed lower Ptch expression in 
Chmp1a null cerebellum that was especially pronounced in the Shh-responsive EGL (Figure 
3E), providing further evidence for decreased Shh signaling in the absence of Chmp1a. 
 
Chmp1a is required for Shh secretion in vivo 
Direct measurement of total Shh protein concentration with a highly sensitive ELISA 
assay showed 40% less Shh in embryonic CSF from Chmp1a null mouse embryos compared to 
controls at E14.5 (two-tailed t-test, p = 0.009; Figure 3F), providing direct evidence that 
Chmp1a is required for Shh secretion in the developing brain. In parallel, SAG stimulation of 
Chmp1a null and control MEFs showed no significant defect in downstream Shh signaling as 
measured by Gli1 activation (two-tailed t-test, p = 0.39; Figure S6B), consistent with Chmp1a 
acting upstream of Shh. Furthermore, we performed a rescue experiment with a Ptch 
heterozygous null mouse, a genetic tool that increases Shh signaling in vivo (Goodrich et al., 
1997), and found that Chmp1a null embryo microcephaly at E18.5 was reversed in Chmp1a null 
: Ptch heterozygous embryos and not significantly different from control (two-tailed t-test, p = 
0.22, Figure S6A). This result provides further evidence that microcephaly in Chmp1a null mice 
reflects decreased Shh function. 
 
CHMP1A is essential for human cerebral organoid formation 
To further examine CHMP1A’s role in SHH-driven neuroprogenitor proliferation, we 
generated CHMP1A null human cerebral organoids using CRISPR/Cas9 mutagenesis and found 
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impaired progenitor maintenance and premature neuronal differentiation (Figures 4, S7A). 
Immunostaining of day 38 organoids for PAX6 and CTIP2 showed a 67% loss of PAX6-positive 
progenitor cell area and 123% gain of CTIP2-positive postmitotic neurons (two-tailed t-test, 
CTIP2: p = 0.001, PAX6: p = 0.003, Figures 4B, 4C). RNA sequencing of iPSCs before 
differentiation, organoids at day 14 during differentiation, and organoids at day 38 after 
differentiation (Figure S7B, S7C) further defined the defect in organoid formation as impaired 
progenitor maintenance and premature neuronal differentiation. GO pathway analysis of 
upregulated genes in CHMP1A null organoids showed enrichment of terms for neuronal 
differentiation (Figure 4D). RNA sequencing revealed distinct groups of up- and down-regulated 
genes in the absence of CHMP1A including loss of progenitor markers (SOX1, SOX2, HMGA1, 
and HES5) and early induction of differentiated neuron markers (DCX, SYT4, ROBO2, and 
NRXN1) (DESeq2 adjusted p-value, each gene: p < 0.05, Figures 4E, 4F, Tables S1, S2). 
CHMP1A null day 38 organoids correlate more closely with RNAseq data from GW12 human 
cortex (Allen Institute), while control organoids correlate more closely with GW9 cortex, 
providing additional evidence for premature differentiation (Figure 4G). At day 38, CHMP1A 
null organoids show decreased expression of progenitor marker PAX6 and increased expression 
of post-mitotic neuron marker CTIP2 (Figures 4H). 
 RNA sequencing revealed impaired SHH signaling with 50% reduction of GLI1 
expression in mutant iPSCs at the start of organoid differentiation (DESeq2 adjusted p-value, 
iPSC: p < 0.0001, Figure 4I). Activation of SHH signaling with exogenous administration of 
SAG on differentiation day 35 (with harvest on day 38, Figure 4A) induced GLI1 and PTCH 
expression equally in WT and CHMP1A null organoids (two-tailed t-test, GLI1: p = 0.75, PTCH: 
p = 0.84), suggesting no downstream SHH signaling defect in the absence of CHMP1A (Figure 
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4J). Rather, SAG-induced SHH signaling rescued reduced expression of PAX6 in CHMP1A null 
organoids, a defining marker of impaired progenitor maintenance in the absence of CHMP1A 
(DESeq2 adjusted p-value, no treatment: p < 0.0001, +SAG: p = 0.11, Figure 4K), although 
some gene expression differences were not rescued (Figure S8). These data strongly suggest that 
progenitor proliferation defects in the absence of CHMP1A result from upstream impairment of 
SHH signaling via decreased SHH secretion. 
 
Defective ILV and MVB structure in Chmp1a null embryos 
As Shh secretion has been reported on EVs and ESCRT-III is involved in ILV biogenesis 
in MVBs, we used three-dimensional focused ion bean scanning electron microscopy (FIB-SEM, 
Xu et al., 2017) to examine choroid plexus (ChP) epithelial cells, a primary source of Shh in 
embryonic mouse brain (Nielsen and Dymecki, 2010; Lun et al., 2015a), and found abundant 
MVBs near the ventricular surface (Figure 5). SEM revealed the ChP’s remarkable structure as a 
monolayer of epithelial cells forming grape-like clusters that maximize ventricular surface area 
(Figure 5A) and transmission EM (TEM) showed the ventricular surface cross-section (Figure 
5B). FIB-SEM imaging revealed that 75% of MVBs in ChP epithelial cells were located within 2 
µm of the ventricular surface, indicating some could be secretory MVBs (Figures 5C, 5D). 
Indeed, one MVB showed fusion with the ventricular surface (Figure 5E). CHMP1A 
immunoreactivity in human hindbrain ChP epithelial cells distributed together with CD63-
immunoreactive MVBs near the ventricular surface (Figure S9A) providing additional evidence 
of secretory MVBs. MVB fusion with the plasma membrane releases ILVs as EVs and exosomes 
(Tietje et al., 2014). Thus, our imaging provides evidence that ChP epithelial cells are a source of 
EVs in the developing brain. 
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TEM showed disrupted MVB structure in Chmp1a null embryonic ChP. The number of 
ILVs per MVB was 33% lower in mutant ChP epithelial cells than in control (Mann-Whitney 
test, p = 0.0003; Figures 5F, 5G, S9C), and some Chmp1a null MVBs contained abnormally 
large ILVs (Figure 5F, arrowhead), a known consequence of impaired ILV budding (Lee et al., 
2007). Apart from the observed defects in EV biogenesis, the ChP ventricular surface and 
microvilli appeared otherwise normal in Chmp1a null embryos (Figures S9B). As in ChP 
epithelial cells, P0 mutant cerebellar PC MVBs showed 22% fewer ILVs per MVB compared to 
controls (Mann-Whitney test, p = 0.0005; Figures 5H, 5I, S9D). These data raise the possibility 
that defective Shh secretion into the CSF and from PCs may involve defective ILV formation in 
the MVB. TEM showed MVBs are abundant in dendrites of both PC and cortical projection 
neurons. At P4, cerebellar PC MVBs are common in the dendrites that extend towards the EGL 
where Shh-responsive GCPs are located (Figures S10A, S10B). In mouse cerebral cortex, serial 
reconstruction of hundreds of TEM images of cortical pyramidal neurons (Lee et al., 2016) 
shows that MVBs are surprisingly abundant in pyramidal cell dendrites (Figure S10C). The 
dendritic arbor and axon of a single pyramidal cell contained at least 80 MVBs, often near 
synapses, which could be interpreted as active dendritic EV secretion sites. Indeed, Shh released 
from pyramidal cell dendrites during postnatal development is required for synapse formation 
between layer V corticofugal projection neurons and callosal projection neurons in the cortex 
(Harwell et al., 2012). These finding suggest EV-mediated secretion is widespread across 
multiple time points and anatomic regions of the developing brain. 
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CHMP1A is required for vesicular SHH secretion in vitro  
To dissect the mechanism underlying regulation of SHH secretion by CHMP1A, we used 
the human fetal glial cell line SVG-A and generated CHMP1A null monoclonal lines through 
CRISPR/Cas9 mutagenesis (Figures S11A, S11B). TEM of mutant cells showed a 32% 
reduction of ILVs per MVB in CHMP1A null compared to WT (Mann-Whitney test, p = 0.0012; 
Figures 6A, 6B), confirming our in vivo results from choroid plexus and Purkinje cells (Figure 
5). Serial ultracentrifugation of conditioned medium obtained from SHH-expressing SVG-A 
cells enabled EV collection and initial separation based on size (Kowal et al, 2016, Methods, and 
Figure 6C): large EVs and cell debris pelleted in the 2K fraction, medium-sized EVs in the 10K 
fraction, and small EVs and exosomes in in the 100K fraction. The exosome-specific markers 
CD9, CD81, CD63, TSG101 and Syntenin were either restricted to or highly enriched in the 
100K pellet, while exosome-excluded markers, such as actin and ER-resident protein GP96 were 
absent from this fraction (Figure 6D), confirming previous reports (Lotvall et al., 2014). In the 
CHMP1A null 100K pellet, CD63 was decreased 46% and Syntenin was decreased 55% (two-
tailed t-test, CD63: p = 0.001, Syntenin: p = 0.037), while CD9, CD81, and TSG101 were not 
detectably changed (two-tailed t-test, CD9: p = 0.42, CD81: p = 0.75, TSG101: p = 0.61, Figure 
6E). Although SHH was detected in all vesicular fractions, it was significantly decreased only in 
the 100K EV fraction derived from CHMP1A null SVG-A cells (49% reduction, two-tailed t-test, 
p = 0.003, Figure 6F). Similar results were obtained using a heterogeneous pool of CHMP1A 
null cells (Figure S11C) instead of a monoclonal population. Importantly, the 100K fraction 
contained biologically active SHH that induced Gli1 expression in NIH3T3 cells. At equal 
protein content, the signaling potency of the 100K EV fraction was reduced 79% in CHMP1A 
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null cells compared to EVs of WT cells (6ug protein, two-tailed t-test, p = 0.008, Figure 6G), 
demonstrating that CHMP1A is required for secretion of active SHH-containing small EVs.  
 
SHH is secreted on specialized EVs  
Because the 100K pellet formed following ultracentrifugation is a complex mixture of 
several distinct EVs subtypes, we next used immunoisolation to determine which subtype 
contained SHH-positive vesicles (Kowal et al., 2016, Figure 7A). We immunoisolated with anti-
CD9 or anti-CD63 antibodies to test for the presence of SHH on exosomes. Western Blot (WB) 
analysis of bound and unbound material showed modest SHH amounts on CD9-positive EVs and 
minimal SHH on CD63-positive EVs (Figure 7B). Similarly, we observed minimal co-
localization of SHH and either CD9 or CD63 by confocal immunofluorescence microscopy 
(Figure 7C), suggesting that most SHH in the 100K fraction is secreted on vesicles distinct from 
exosomes. To then define the hallmark of SHH-bound vesicles, we immunoisolated SHH 
positive EVs from the 100K pellet and subjected the bound material to mass spectrometry 
analysis to identify other components of these EVs (Figure 7D). This analysis revealed a unique 
set of proteins significantly enriched in the SHH fraction, including Ras-related protein Rab-18 
(RAB18), Tyrosine-protein kinase receptor UFO (AXL) and Transmembrane emp24 domain-
containing protein 10 (TMED10), that have not been reported as major components of exosomes 
(Welch’s t-test, RAB18: p = 0.008, AXL, TMED10: p < 0.001, Figure 7E, Table S3, Lotvall et 
al., 2014). Moreover, the exosomal markers CD63, CD9 and Syntenin were not enriched, while 
CD81 was present (Table S3). By immunoprecipitation of CD63 or SHH, we found that RAB18, 
AXL, and TMED10 mark a specific EV subtype that is distinct from CD63-positive exosomes 
(Figure 7F), which we label ART-EVs (AXL, RAB18, and TMED10). 
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CHMP1A is present on ART-EVs  
ESCRT components participate in the process of exosome biogenesis, but they are also 
found associated with EVs in the extracellular environment (Chiasserini et al., 2014). To 
investigate whether CHMP1A is associated with ART-EVs, we isolated SHH-containing vesicles 
from the 100K fractions of SVGA WT and CHMP1A null cells by immunoprecipitation. WB 
analysis of the bound fractions revealed the presence of CHMP1A only in the ART-EVs 
recovered from WT cells, confirming the specificity of the detection (Figure S12A). In contrast, 
AXL and RAB18 were similarly detected in ART-EVs from both WT and CHMP1A null cells. 
High-resolution time-lapse confocal microscopy of the intracellular co-distribution of ectopically 
expressed SHH and CHMP1A in live SVG-A cells showed that both proteins distributed mostly 
in independent compartments, but a subset of CHMP1A and SHH structures overlap over time 
(Figure S12B, Supplemental Movie). Taken together, these findings suggest that CHMP1A 
physically associates with SHH-positive ART-EVs. To confirm that ART-EVs are present in the 
adult nervous system in vivo, we isolated the 100K EV fraction from human adult CSF (collected 
from a patient with glioblastoma multiforme) and purified SHH-containing vesicles as well as 
CD63-positive exosomes from the 100K CSF pellet by immunoprecipitation. Pulldown of SHH 
co-purified AXL and RAB18, which were absent from the CD63-positive exosome fraction 
(Figure 7G), thus confirming the specific protein signature of ART-EVs identified in SVG-A 
cells. Together, our data strongly suggest that SHH is secreted in vivo on a novel EV subtype: 
ART-EVs. 
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DISCUSSION 
By characterizing Chmp1a null mice and CHMP1A null human cerebral organoids we 
show that CHMP1A is essential for neural progenitor proliferation and maintenance. Further, we 
demonstrate that ESCRT-mediated release of extracellular vesicles is impaired in the absence of 
CHMP1A and that this reduces secretion of vesicle-bound SHH, a key driver of progenitor 
proliferation in the brain. Although loss of an ESCRT-III component could cause widespread 
defects resulting from impaired vesicle release, essentially all of the neurodevelopmental defects 
seen in Chmp1a null mice (and CHMP1A deficient humans) can be ascribed to defective SHH, 
and we show that defect lies in SHH secretion. We define a new EV subtype, ART-EVs, on 
which SHH is secreted, and show that ART-EVs exist in vivo. Our findings provide evidence for 
a new mechanism of SHH secretion in vertebrate brain development with broad potential 
relevance to secretion of growth factors and bioactive molecules in the CNS. 
 
Chmp1a null phenotype is consistent with hypomorphic Shh signaling  
All of the most obvious neurodevelopmental defects in Chmp1a null mice—including a 
thin cerebral cortex, small basal ganglia, cerebellar hypoplasia, small somatic size, and perinatal 
lethality—are consistent with partial loss of Shh, since these defects have been observed in 
previous mouse models of decreased Shh signaling through hypomorphic alleles (Huang et al., 
2007, Chamberlain et al., 2008). In addition, both impaired progenitor maintenance in CHMP1A 
null organoids and microcephaly in Chmp1a null mice can be partially rescued by downstream 
Shh signaling activation either chemically or genetically. On the other hand, the lack of digit or 
spinal cord patterning defects in Chmp1a null mice compared to null Shh mutations (Zhu and 
Mackem, 2011, Fuccillo et al., 2006) is consistent with our observed incomplete blockage of Shh 
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secretion and the observation that spinal cord Shh is secreted on large EVs (Tanaka et al., 2005) 
whereas depletion of CHMP1A specifically impairs secretion of SHH on small EVs (Figure 6F). 
The early lethality of Chmp1a null mice precludes identification of additional effects that might 
reflect regulation of other signaling pathways, and the incomplete correction of defects in some 
progenitor and differentiation markers in CHMP1A null organoids by SAG (Figure S8) also 
leaves open the possibility that CHMP1A may regulate other pathways. 
 
Multiple specialized SHH secretion mechanisms  
In vivo Hedgehog (Hh) secretion has been studied primarily in Drosophila imaginal disk, 
where the proposed underlying mechanism remains controversial. Matusek et al. showed Hh 
secretion occurs on larger EVs called ectosomes released from the plasma membrane in an 
ESCRT-dependent manner (Matusek et al., 2014). In their study, disruption of MVB biogenesis 
did not impair Hh secretion, suggesting it did not occur via MVB-derived exosomes. In contrast, 
Parchure et al. reported Hh secretion via ESCRT-mediated exosome-like vesicles derived from 
MVBs (Parchure et al., 2015). Shh secretion at the embryonic mouse ventral node appears to 
occur via large, plasma membrane derived EVs (Tanaka et al., 2005), which are not obviously 
impaired in the absence of Chmp1a. These results highlight the complexity and confusion 
surrounding vesicular Shh secretion, but our data show, for the first time, that Shh secretion on 
small EVs is essential during brain development and specifically impaired by loss of CHMP1A. 
 
SHH secretion via ART-EVs 
We report SHH secretion on a novel class of EVs, ART-EVs, defined by marker proteins 
distinct from classical CD63-positive exosomes. To our knowledge, RAB18, AXL, and 
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TMED10 have not been previously reported as components of SHH-positive EVs, and so can 
provide new insights into the mechanism of SHH secretion. RAB18 is a protein with emerging 
roles in ER to Golgi retrograde trafficking and other cellular trafficking (Vazquez-Martinez et 
al., 2007, Dejgaard et al., 2008) and LOF mutations in RAB18 are associated with Warburg 
Micro syndrome, establishing a critical role of RAB18 in eye and brain development and 
neurodegeneration (Bem et al., 2011). The vesicular proteins AXL and TMED10 may function in 
biogenesis of specific vesicles in SHH producing cells as AXL is a receptor tyrosine kinase 
expressed at the plasma membrane that is required in microglia for apoptotic cell removal 
(O’Bryan et al., 1991, Fourgeaud et al., 2016) and TMED10 (TMP21/P23) is a transmembrane 
protein that is involved in early secretory pathway trafficking and is a member of the Presenilin 
complex (Blum et al., 1996, Chen et al., 2006). ART-EVs may originate from MVBs, like bona-
fide exosomes, or may bud from the plasma membrane. Further work is required to determine the 
similarities and differences between ART-EV and exosome secretion pathways.  
 
CHMP1A regulates secretion of multiple EV subtypes 
Previous studies have established important roles for different members of the ESCRT 
machinery in ILV biogenesis (Colombo et al., 2013; Baietti et al., 2012). We found fewer ILVs 
within MVBs in the absence of CHMP1A and consistent with this phenotype, observed a 
decrease in exosome secretion. Exosomes have been defined as EVs of MVB origin co-enriched 
in tetraspannins CD9, CD81 and CD63, and endosome markers TSG101 or Syntenin (Lotvall et 
al., 2014). However, in our experimental system, we observed reduced secretion of some, but not 
all exosome markers, indicating the existence of a heterogeneous exosomal population among 
EVs. This idea is supported by our immunoprecipitation assay, in which only residual amounts 
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of CD63 were co-isolated with CD9 by anti-CD9 antibodies, and vice-versa (Figure 7B), even 
though both CD63 and CD9 are canonical exosome markers. This finding supports previous 
work suggesting that exosomes are heterogeneous with respect to their size and cargo, that cells 
contain distinct MVBs, and that ILVs of the same MVB display different structures and 
compositions (Colombo et al., 2013, Bobrie et al., 2012, van Niel et al., 2001, Fevrier and 
Raposo, 2004, Mobius et al., 2002, White et al., 2006). With these results in mind, it is 
reasonable to suggest that decreased ILV count in CHMP1A null MVBs underlies reduction of 
both SHH positive ART-EVs and CD63-positive exosomes. 
 
Many potential EVs function in the CNS 
 Whereas the developmental defects caused by the absence of CHMP1A—microcephaly, 
cerebellar hypoplasia, and short stature—highlight the importance and widespread function of 
EV-mediated cellular communication during development, the persistence of ART-EV’s in the 
adult human CSF suggests that there may be continued requirements for EV-mediated growth 
factor secretion in adult brain. The widespread distribution of MVBs along dendrites of 
pyramidal neurons in the cerebral cortex hints at complex forms of cellular communication, 
perhaps involving retrograde synaptic signaling. Moreover, there is evidence that EV secretion 
may be hijacked during the pathologic spread of Tau protein that may underlie neuronal 
degeneration (Asai et al., 2015). In providing the first animal model with specific defects in EV 
function in the CNS, we provide a potential tool to assess the functions of EVs in these diverse 
and fundamental processes.  
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Figure 1: Chmp1a is essential for brain development in mice 
(A) P0 Chmp1a null pups are smaller than littermate controls. (B) P0 Chmp1a null pups have 
smaller brains than controls. Note smaller olfactory bulbs and shorter A-P length of the cortex. 
(C) Body mass is reduced in Chmp1a null embryos, E16.5: Control: n=7, Chmp1a null: n=2; 
E18.5: Control: n=6, Chmp1a null: n=1; P0: Control: n=17, Chmp1a null: n=2. (D) Brain mass is 
reduced in Chmp1a null embryos, E14.5: Control: n=10, Chmp1a null: n=5; E16.5: Control: n=6, 
Chmp1a null: n=2; E17.5: Control: n=23, Chmp1a null: n=4; E18.5: Control: n=20, Chmp1a 
null: n=3; P0: Control: n=9, Chmp1a null: n=3. (E) The cortical plate is 13% thinner in Chmp1a 
null embryos at E18.5, Control: n=11, Chmp1a null: n=5. (F) Striatum area is reduced by 25% at 
E18.5 in Chmp1a null embryos compared to controls, Control: n=8, Chmp1a null: n=3. (G) P0 
midline section shows cerebellar hypoplasia (18% reduction) in Chmp1a null pups compared to 
control littermates, Control: n=7, Chmp1a null: n=4. (H) Quantification of E-G. Two-tailed t-
test, * p < 0.05, ** p < 0.01, *** p < 0.001.  
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Figure 2: Chmp1a is expressed in neurons and ChP epithelial cells in developing brain 
(A) In P4 cerebellum, Chmp1a-LacZ is detected in Purkinje cell layer and absent from EGL. 
LacZ is also strongly expressed in hindbrain ChP. (B) Chmp1a immunoreactivity in cerebellar 
Purkinje cells (P4). Merge of Calbindin and Chmp1a highlights Chmp1a in Purkinje cell 
cytoplasm and dendrites (arrowhead) with absence in the nucleus (asterisk). (C) RNAscope 
expression of CHMP1A, SHH, and PTCH in developing human cerebellum. (D) RNAscope 
expression of CHMP1A, SHH, and CD63 in developing human cerebellum. (E) Mouse Chmp1a 
protein is expressed in post-mitotic neurons (Ctip2) in the cerebral cortex but not in progenitors 
(Sox2) at E14.5. (E) CHMP1A, PTCH, and CD63 expression in developing human cortex by 
RNAscope shows analogous localization. All panels are representative image of ≥2 experiments. 
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Figure 3: Chmp1a is required for progenitor proliferation in telencephalon and hindbrain 
(A) Chmp1a null P0 pups have 38% fewer mitotic GCPs than control littermates, Control: n=7, 
Chmp1a null: n=4. (B) 19% reduction in pH3 positive mitotic cortical progenitors at E14.5 
Chmp1a null embryos, Control: n=13, Chmp1a null: n=10. (C) E13.5 Chmp1a null embryos 
have 26% fewer Tbr2 positive intermediate progenitors than controls, Control: n=6, Chmp1a 
null: n=6. (D) MGE and LGE show 43% fewer pH3 positive mitotic progenitors in Chmp1a null 
embryos, Control: n=3, Chmp1a null: n=3. (E) ISH for Ptch shows reduced expression in 
Chmp1a null P0 cerebellum. Control: n=4, Chmp1a null, n=3. (F) CSF concentration of Shh in 
4th ventricle at E14.5 is reduced 38% in Chmp1a null embryos, Control: n=10, Chmp1a null: 
n=5.  Two-tailed, unpaired t-test, * p < 0.05, ** p < 0.01. 
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Figure 4: CHMP1A is essential for progenitor proliferation in human cerebral organoids 
(A) Human cerebral organoid differentiation protocol. (B) Organoids contain cortical progenitors 
(red, immunostained for PAX6, arrowheads) surrounded by postmitotic neurons (green, 
immunostained for CTIP2). (C) PAX6 area is decreased and CTIP2 area is increased in 
CHMP1A null organoids, Control: n=13, Chmp1a null: n=10. (D) GO pathway enrichment 
analysis. (E) RNA sequencing reveals clusters of genes up- and down-regulated in CHMP1A null 
organoids. (F) Expression of proliferative marker genes is decreased in CHMP1A null organoids 
while expression of differentiation and post-mitotic neuron markers is increased. (G) 
Comparison of organoid gene expression profiles to expression profiles of human fetal cortex. 
(H) Decreased PAX6 expression and increased CTIP2 expression by RNA sequencing at day 38 
in CHMP1A null organoids. (I) Decreased GLI1 expression in CHMP1A null iPSCs. (J) SAG 
treatment of organoids induces GLI1 and PTCH expression. (K) SAG treatment partially rescues 
decreased PAX6 expression in CHMP1A null organoids. C, J: Two-tailed, unpaired t-test; F, H, I, 
K: DESeq2 adjusted p-value; * p < 0.05, ** p < 0.01, *** P < 0.001. 
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Figure 5: Chmp1a is essential for ILV formation in developing mouse brain  
(A) SEM of mouse embryonic hindbrain ChP. (B) TEM of mouse embryonic hindbrain ChP. (C) 
FIB-SEM of mouse ChP revealed accumulation of MVBs near epithelial cell ventricular surface. 
(D) Quantification of MVB distribution within epithelial cells. (E) MVB fused with plasma 
membrane of ChP epithelial cell (arrowhead). (F) Fewer ILVs in Chmp1a null ChP MVBs and 
abnormally large ILVs (arrowhead). (G) Quantification of (F), Control: n=88 MVBs (7 
embryos), Chmp1a null: n=39 MVBs (2 embryos). (H) Fewer ILVs in Chmp1a null Purkinje 
cells. (I) Quantification of (H), Control: n=88 MVBs (6 embryos), Chmp1a null: n=74 MVBs (2 
embryos). G, I: Mann-Whitney test, *** p < 0.001. 
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Figure 6: CHMP1A depletion decreases secretion of SHH and exosomes in vitro 
(A) Decreased ILV formation in MVBs of CHMP1A null SVG-A cells compared to WT (TEM). 
(B) Quantification of (A), Control: n=41, CHMP1A null: n=46. (C) EV isolation procedure 
(Kowal et al, 2016). (D) Representative WB analysis of isolated EVs (2K, 10K, 100K pellets) 
from WT and CHMP1A null SVG-A cells expressing SHH. Blot shows EV-specific markers 
(CD9, CD63, CD81, Syntenin, TSG101), EV-excluded markers (GP96, Actin), CHMP1A, and 
SHH. (E) Quantification of (D), Wild type: n=4, CHMP1A null, n=4. (F) Quantification of SHH 
WB signals in the 2K, 10K and 100K fractions, Wild type: n=4, CHMP1A null, n=4. (G) Gli1 
induction in NIH3T3 cells induced by 100K pellet from SHH transfected SVG-A cells. 1ug, 3ug: 
Wild type: n=6, CHMP1A null: n=6. 6ug: Wild type: n=5, CHMP1A null, n=6. B: Mann-
Whitney test, ** p < 0.01. E-G: two-tailed, unpaired t-test, * p < 0.05, ** p < 0.01. 
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Figure 7: SHH is secreted on a novel EV subtype, ART-EVs 
(A) Scheme of exosome isolation from the 100K pellet by immunoprecipitation using beads 
coupled to CD9, CD63 antibodies or mouse Pan-IgG antibodies. Both bound (pull-down) and 
unbound (flow-through) material was recovered. (B) Representative WB of the bound and 
unbound fractions from exosome immunoisolation, probed with antibodies against CD9, CD63 
and SHH. Note that most SHH does not co-purify with exosomes, but remains in the FT fraction. 
(C) Immunostaining of exosomal markers CD9 or CD63 in cells ectopically expressing 
mNeonGreen-SHH. (D) SHH-positive vesicles were purified from the 100K pellet by 
immunoisolation using anti-SHH antibodies. (E) Peptides enriched in EVs isolated by SHH 
immunoisolation. (F) Immunoisolated SHH-positive vesicles and CD63-positive exosomes were 
subjected to WB analysis, confirming the exclusive presence of RAB18, AXL and TMED10, in 
purified SHH-vesicles. In contrast, Syntenin is only found on CD63-positive exosomes, while 
CD81 is present on both type of vesicles. (G) SHH- and CD63-positive vesicles from the 100K 
pellet were immunoisolated from human CSF and subjected to WB analysis, confirming the 
exclusive presence of RAB18 and AXL on ART-EVs in vivo. * indicates non-specific band. 
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Supplemental Information  
 
STAR  METHODS  
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by Lead Contact, Christopher A. Walsh (christopher.walsh@childrens.harvard.edu). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Human Samples 
Operating under an approved institutional review board (IRB) protocol, normal human choroid 
plexus was identified and collected at autopsy by pathologists at Boston Children's Hospital. 
 
Operating under an approved institutional review board (IRB) protocol, human CSF was 
collected by neurologists at Beth Israel Deaconess Medical Center. 
 
Operating under an approved institutional review board (IRB) protocol, GW20 human fetal 
whole brain tissue was collected at autopsy by pathologists at Beth Israel Deaconess Medical 
Center. 
 
Animal Use 
All animals were cared for humanly and all experiments were approved by Boston Children’s 
Hospital IACUC. 
 
Chmp1a GT mouse generation and mouse breeding 
Mouse ES cells with a gene trap cassette inserted into Chmp1a were obtained from 
BayGenomics (B6;129P2-Chmp1aGt(XC472)Byg/Mmucd) and injected into blastocysts of WT mice.  
Resulting chimeras were out crossed with WT C57/Bl6 mice to generate heterozygous GT mice.  
Heterozygous GT mice were backcrossed to C57/Bl6 for 7-8 generations. Mouse DNA was 
genotyped with the following primers: WT primer F: GAGACAGCGGGTCCGTAAC, WT 
primer R: AACACACACTCGAACCGAAAG, GT primer F: GAGACAGCGGGTCCGTAAC, 
GT primer R: GGTCCTAGTCGGAGGTCTCG. 
 
Ptch null mouse 
Ptch null mouse line (Goodrich et al., 1997) was purchased from Jackson Labs and genotyped 
according to their protocol. 
 
CHMP1A null cell line generation 
Monoclonal SVG-A CHMP1A null line and iPSC CHMP1A null lines were generated using 
CRISPR-Cas9 mutagenesis (Veres et al., 2014) Cas9 was expressed from a plasmid encoding 
Cas9 and GFP (Gift of Chad Cowan and Kirin Musunuru). gRNA targeting CHMP1A was 
expressed from a co-transfected plasmid, CHMP1A protospacer sequence: 
GAAGGACTCCAAGGCGGAGC. GFP positive cells were grown as single colonies isolated 
and then sequenced to identify homozygous frame shift mutations in CHMP1A. Controls were 
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monoclonal lines from the same experiments shown to WT by Sanger sequencing.  Primers used 
to genotype were F: GAAGACAGACACTGGAGAAAACC R: 
CAGAAGACAAACCAGGAGAGTCA. 
 
Heterogeneous CHMP1A null cell line generation 
SVG-A CHMP1A null cell line (heterogenous pool of either WT or KO cells) was generated 
using CRISPR-Cas9 mutagenesis (Veres et al., 2014). Cas9 was expressed from a lentiviral 
plasmid (Gift of Feng Zhang, MIT) also encoding the far-red fluorescent protein E2-Crimson, 
the puromycin resistance gene, and gRNA targeting CHMP1A 
(GAAGGACTCCAAGGCGGAGC). Lentivirus was harvested 48 h after transfecting the Cas9 
packaging plasmids together with plasmids encoding HIV Gag-Pol and VSV-G envelope in 
Hek293T cells using JetPrime (Polyplus transfection) according to the manufacturer’s 
instructions. SVG-A cells were incubated with lentivirus for 24 h in the presence of 1 μg/ml 
Polybrene (EMD Millipore). 3 days later, cells were exposed to puromycin (2 μg/ml) for one 
week for selection, after which survivors were bulk sorted by FACS based on high E2-Crimson 
expression. A KO control cell line was generated using a similar strategy and a lentivirus 
construct encoding gRNA targeting the luciferase gene (CTTCGAAATGTCCGTTCGGT).  
 
Cell lines and culture conditions  
Human brain astroglial cells SVG-A and mouse embryonic fibroblasts NIH3T3 were cultured at 
37oC and 5% CO2 in high-glucose DMEM (Gibco) supplemented with 10% FCS and 1% 
penicillin-streptomycin. iPSCs (line IMR90-4, from WiCell) were grown on Matrigel (BD) in 
mTESR media (Stem Cell Tech). MEFs were cultured in DMEM high glucose supplemented 
with 10% FBS, 1% P/S, and 2 mM L-glutamine. 
 
Cerebral organoid culture and isolation 
Cerebral organoids were harvested at 14 days or 38 weeks post differentiation, and generated 
according to the following method: iPSC colonies were grown on a feeder layer of mouse MEFs 
(35,000 cells/cm2) and cultured in W0 medium (DMEM/F12, 20% KOSR, 2mM L-glutamine, 1x 
NEAA, 1x P/S, 50 µM b-mercaptoethanol (Thermofisher) + 8 ng/ml FGF2 (added fresh daily, 
Sigma)). After iPSC colonies reached 2-3mm in diameter, they were lifted with a cell scraper 
and transferred to ultra-low attachment 60mm culture dishes (Corning), containing W0 + 1x 
sodium pyruvate (Differentiation medium, no FGF2). After 24 hours, initial embryoid bodies are 
formed and (day 0) 50% of medium was replaced with Differentiation medium + small molecule 
inhibitors to the following final concentrations: 10 µM SB-431542 (Sigma), 1 µM Dorsomorphin 
(Sigma), 3 µM IWR-1-Endo (Sigma) and 1 µM Cyclopamine (Sigma). Differentiation medium + 
small molecules was then replaced every other day. On day 4, 60mm plates containing organoids 
were placed on a hi/lo rocker inside the incubator. On day 18, medium was replaced with 
Neurobasal/N2 medium (Neurobasal, 1x N2 supplement, 2 mM L-glutamine, 1x P/S) 
supplemented with 1 µM Cyclopamine. On day 26 medium was replaced with Neurobasal/N2 
medium without cyclopamine. At day 35, organoids were culured in Neurobasal/N2 medium 
supplemented with 1 µM SAG (treated), or DMSO (control), and refreshed daily. At day 38, for 
RNA isolation, organoids were isolation in TRIzol (Thermofisher). For immunostainings, 
organoids were washed twice with PBS and fixed by incubated 10 minutes in 3.8% PFA / PBS. 
After fixation, organoids were washed three times in 0.1% BSA / PBS. Then organoids were 
incubated in 15% sucrose / PBS at 4°C for 2 hours, followed by incubation in 30% sucrose / PBS 
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overnight at 4°C. Using a cut off pipette tip, single organoids were transferred to embedding 
molds containing Shandon M-1 embedding matrix (Thermofisher) and stored at -80°C. 
 
Generation of Chmp1a null MEFs 
Chmp1a GT heterozygous mice were crossed and E14-15 embryos were collected.  Embryos 
were decapitated and visceral organs removed.  The remaining tissue was dissociated with 
Trypsin and then plated and maintained in DMEM high glucose supplemented with 10% FBS, 
1% P/S, and 2 mM L-glutamine. MEFs were assayed before passage 4. 
 
METHOD DETAILS 
 
pH3 analysis 
Matching coronal telencephalon sections at E12.5 or E14.5, or midline sagittal cerebellum 
sections at P0 were immunostained for pH3. pH3+ cells lining the cortical ventricular surface 
were counted at E14.5, pH3+ cells in the MGE and LGE were counted at E12.5, and pH3+ cells 
in the cerebellar EGL were counted at P0. 
 
LacZ staining 
Chemical staining for beta-galactosidase activity was performed with the beta-gal staining kit 
from Invitrogen (K146501).  Briefly, tissue was fixed overnight in 2% gluteraldehyde, 
microtome sectioned (70 uM), and then stained for beta-gal activity according to the kit 
instructions. 
 
In situ hybridization 
In situ hybridization was performed as previously described (Arlotta et al., 2005).  Ptch in situ 
probe was a gift from C Cepko and A Joyner. RNA was synthesized with the Megascript kit 
from Invitrogen. DIG dNTPS and anti-DIG Fab fragments were ordered from Roche. 
 
Mouse embryo CSF collection and SHH ELISA 
CSF was collected from the 4th ventricle of E14.5-E15.5 Chmp1a null mouse embryos and 
littermate controls using a pulled micropipette. CSF was centrifuged at 10000 G for 5 minutes 
and then used in the SHH ELISA. SHH ELISA kit was purchased from R and D systems 
(MSHH00) and used according to the manufacture’s instructions. 
 
Human choroid plexus immunostaining 
Choroid plexus tissue was fixed in 4% PFA, frozen, and sectioned at 15 um on a cryostat.  
Cultured iPSCs were fixed with 4% PFA for 10 minutes at RT.  Tissue or cells were 
permeabilized with 0.04% Tween in PBS and blocked in 0.04% tween, 2.5% donkey serum, and 
2.5% goat serum in PBS.  Sections or cells were incubated with primary antibody diluting in 
blocking buffer overnight at 4C.  Sections or cells were then stained with Alexa secondary 
antibodies and Hoechst.  Imaging was done on Zeiss 510 confocal microscope. 
 
Mouse brain and human organoid immunostaining 
Tissue was fixed overnight at 4 C in 4% PFA and sectioned at 70um using a Vibratome.  Antigen 
retrieval was performed with Retrievagen A.  Tissue was permeabilized and blocked in 3% BSA, 
0.3% Triton X-100, 0.3% sodium azide in PBS.  Primary antibodies were diluted in blocking 
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buffer and incubated overnight at 4 C.  Sections were then stained with Alexa secondary 
antibodies and Hoechst.  Imaging was done on Zeiss 510 confocal microscope. 
 
Two results confirm the specificity of the CHMP1A antibody used for immunostaining 
(ProteinTech 15761-1-AP). First, immunoblot of Chmp1a null MEF cell lysate with this 
antibody shows no reactivity (Figure 1B). Second, tissue sections from Chmp1a null mice 
incubated with this antibody show nearly complete loss of signal (Figure S3B). 
 
RNAscope 
RNAscope on human fetal brain tissue was performed according to manufacturer’s protocol 
(ACDBio). 
 
RNA sequencing library preparation 
Cerebral organoid RNA was isolated according to standard TRIzol protocol. RNA was treated 
with DNAseI (Roche) according to standard protocol for DNA clean-up in RNA samples. RNA 
was then isolated by column purification (Zymo RNA clean & concentrator 5) and stored at -
80°C. For RNA sequencing, first mRNA was isolated from total RNA using polyA selection 
Dynabeads mRNA DIRECT Micro Purification Kit (Thermofisher). Library was prepared using 
strand-specific Ion Total RNA-Seq Kit v2 (Thermofisher) and Ion Xpress RNA-Seq Barcode 1-
16 (Thermofisher) to label different samples. Sequencing was done using IonProton sequencer, 
generating single-end reads of around 100bp in length (Thermofisher). 
 
Mapping of RNA sequencing data 
RNA sequencing data was processed using the Tuxedo package. Briefly, samples were mapped 
using Tophat2 (Kim et al., 2011), using Bowtie2 (Langmead and Salzberg, 2012) as the 
underlying alignment tool. The iPSC input fastq files consisted of paired end reads with each end 
containing 100bp for iPSC data. The cerebral organoid input fastq consisted of single-end reads 
of around 100bp length for cerebral organoid data. The target genome assembly for these 
samples was GRCh38/UCSC hg38, and Tophat was additionally supplied with the gene 
annotation of ENSEMBL84 (GRCh38.p5). Reads mapped per exon were counted using HT-Seq 
count (union mode) and summed per corresponding gene. HT-Seq count output was normalized 
using DESeq2, and pairwise comparisons were made to determine significant differences in 
control and CHMP1A null iPSCs or cerebral organoids.  For generation of heatmaps, z-score was 
calculated using log-transformed normalized counts. Expression level and fold-change for all 
mapped transcripts are provided in Supplemental Table 1.  
 
GO pathway enrichment analysis 
For genes with at least a 2-fold change between wild type and CHMP1a null, enrichment of gene 
sets for GO- Biological Processes (BP-FAT) and KEGG-pathways was determined by DAVID 
(Database for Annotation, Visualization and Integrated Discovery) Functional Annotation 
Clustering (v6.7). For each analysis raw RNAseq read counts were normalized using DEseq2. 
For week 2 and week 5 respectively, all genes with mean read count >64 and read count >32 
were included as background.  Clusters of GO-terms and KEGG pathways were manually given 
a name that best represented all individual GO-term categories within each cluster. The DAVID 
Functional Annotation Tool provides an ‘enrichment score’ but does not provide a measure of 
statistical significance for Functional Annotation Clusters. For each Functional Annotation 
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Cluster, the benjamini-corrected p-value for the highest-ranking individual GO-term in each 
cluster is displayed next to the bar graphs. GO analysis results and input gene lists are provided 
in Supplemental Table 2. 
 
For figure 4D, the top 250 differentially expressed genes (DESeq2) were selected at d14 or d38 
samples from pairwise comparisons between CHMP1A null and control cerebral organoids. 
Upregulated or downregulated genes were placed into separate gene lists. Analysis was done 
using Panther Overrepresentation test on GO biological processes with Bonferroni correction. 
Background gene list consisted of all genes, which had on average 10 counts or more mapped in 
the analyzed samples. In this analysis, the downregulated genes did not show relevant 
enrichment for brain related GO terms. For supplemental figure 7C, the analysis was also done 
according to these parameters. Genes that were already differentially expressed between 
untreated d38 control and d38 CHMP1A null organoids were excluded. The remaining genes 
were selected by DESeq2 adjusted p-value < 0.01 instead to limit the amount of genes for 
analysis.  
 
Gene expression correlation human brain and cerebral organoids 
Cerebral organoid RNA-seq data was compared to developing human brain RNA-seq data 
(Brainspan, Allen institute). For Figure 4G, d14 and d38 CHMP1A null and control organoids, 
the top 250 differentially expressed genes (DESeq2) were selected. For supplemental figure 7A / 
B, genes with adjusted p-value < 0.01 were selected to limit the number of genes for analysis. 
Their corresponding expression data was acquired from Brainspan data. Cerebral organoids have 
best correlation with Brainspan week 9 dorsofrontal cortex data (w9 DFC). Several other time-
points of DFC data were used to assess temporal identity of organoids. Genes were ranked by 
their expression level from high to low, using normalized counts for organoid data, and FPKM 
for Brainspan data. Then, pairwise calculation of Spearman’s rank correlation was done for each 
pair and plotted using multi-experiment viewer. 
 
Shh signaling in MEFs 
MEFs from Chmp1a null embryos and littermate controls were cultured as described above.  The 
cells were then cultured in 0.5% FBS with 1 uM SAG for 48 hours.  Then total RNA was 
isolated with RNeasy kit (Ambion) and cDNA was created with Superscript III kit (Invitrogen).  
Taqman qRT-PCR assay was run on StepOnePlus (Applied Biosystems) with probes for Axin2 
and Beta-actin to measure gene expression.   
 
Extracellular vesicle isolation 
SVG-A cells were either mock-transfected or transfected with a plasmid encoding hSHH using 
JetPrime according to the manufacturer’s instructions. 24 h later, cells were washed once with 
PBS and cultured for another 48h in media supplemented with exosome-depleted FBS (System 
Biosciences) instead of normal FBS, before harvesting cells for lysis and supernatants (SN) for 
EV isolation. EVs were isolated from conditioned media by differential ultracentrifugation as 
previously described (Kowal et al., 2016). Briefly, SN was centrifuged for 10 min and 300xg to 
pellet cells and large debris. The SN was transferred to new tubes and further centrifuged at 
2,000xg for 20 min to obtain the 2K pellet. The resulting SN was then transferred to 
ultracentrifuge tubes and centrifuged in an SW28 rotor (Beckman Coulter) for 40 min at 
10,000xg (10K pellet) before a final centrifugation at 100,000xg using the same rotor (100K 
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pellet). Except for the 300xg pellet, all pellets were washed in 5 ml PBS before being 
recentrifuged at the same speed using a SW55Ti rotor (Beckman Coulter) and finally 
resuspended in 50 μl cold PBS. All steps were performed at 4oC. The 300xg pellet was pooled 
with cells harvested from dishes for lysis and WB analysis.  
 
A similar protocol was applied for the isolation of EVs from human CSF (18 mL). 
 
Immunoisolation pull-down assays 
2 μg of either anti-CD9 (Milipore), anti-CD63 (Pelicluster), anti-Shh (Abcam) or Mouse IgG 
antibodies were coupled overnight to 1 mg of magnetic Dynabeads using Dynabeads Antibody 
coupling kit (Invitrogen) according to the manufacturer’s instructions. As described in Kowal et 
al., 2016, coated beads were washed twice in 1 ml washing buffer (PBS-Tween 0.001%) and 
incubated overnight using rotation at 4oC with 10 μg of EVs from the 100K pellet resuspended in 
500 μl of washing buffer. Beads were washed five times with washing buffer, and, where 
indicated the unbound material was pooled together with the SN of the washes and centrifuged at 
100000xg in a SW55Ti rotor for concentration. Both bound material (PD) and unbound material 
pellet (FT) were resuspended in 30 μl of 2x SDS-PAGE sample buffer (Bio-Rad) and boiled for 
5 min at 95oC prior to loading on gel. For MS analysis, Shh pull-down reaction was scaled-up 
approximately five times.  
 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
Samples were lysed using Laemmli buffer (10 mM Tris pH 6,8 ; 1mM EDTA ; 5% ß-
mercaptoethanol ; 5% SDS ; 10% glycerol) and were homogenized during 40 minutes. Samples 
were briefly centrifuged and the supernatant was collected leaving the magnetic beads in the 
tubes thanks to a magnet. Samples were then frozen at -80°C until use. Protein concentrations 
were determined using the RC-DC protein assay (Bio-Rad, Hercules, USA) according to the 
manufacturer’s instructions using BSA as standard. 
 
50 µL of each sample were concentrated down to 20 µL (SpeedVac, Savant, Thermo Fisher 
Scientific, Waltham, USA) and heated at 95°C for 5 minutes before being loaded onto an in-
house poured 1D SDS-PAGE stacking gel in order to focus proteins into a single “stacked” band. 
Electrophoresis was performed under a continuous voltage of 50 V for 40 minutes. The proteins 
were fixed with 50% ethanol and 3% phosphoric acid. After three washes, gels were stained with 
Colloidal blue. 
 
For each sample, the “stacked” protein-band was excised and cut into four equal pieces. After 
destaining, DTT reduction and IAM alkylation using an automatic pipetting device (MassPrep, 
Waters, Milford, MA, USA), proteins were in-gel digested with trypsin (Promega, Madison, WI, 
USA) overnight at 37°C. Tryptic peptides were extracted first in 60 % acetonitrile/0.1 % formic 
acid in water for 90 minutes, followed by a second extraction in 100% acetonitrile for 10 
minutes, at 450 rpm on an orbital shaker. Acetonitrile was evaporated under vacuum and samples 
were adjusted to 8µL using 0.1% formic acid before nanoLC-MS/MS analysis. 
 
NanoLC-MS/MS analyses were performed on a nanoACQUITY Ultra-Performance-LC system 
(UPLC) coupled to a Q-Exactive Plus Orbitrap (Thermo Fisher Scientific) mass spectrometer. 
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The Q-Exactive Plus Orbitrap mass spectrometer is equipped with a nanoelectrospray ion source. 
The UPLC system consisted of a solvent degasser nanoflow pump, a thermostat-controlled 
column oven set to a temperature of 60 °C and a thermostat-controlled autosampler at 10 °C. 
Mobile phase A (99.9% water and 0.1% FA) and mobile phase B (99.9% acetonitrile and 
0.1%FA) were delivered at 450 nL/min by the nanoAcquity. Samples were loaded into a 
Symmetry C18 precolumn (0.18 x 20 mm, 5 μm particle size, Waters) over 3 minutes in 1% 
buffer B at a flow rate of 5 μL/min. Sample loading was followed by reverse-phase separation at 
a flow rate of 450 nL/min using an ACQUITY UPLC® BEH130 C18 separation column 
(200mm x 75 μm id, 1.7 μm particle size, Waters). The Q-Exactive plus Orbitrap instrument was 
operated in data-dependent acquisition mode by automatically switching between full MS and 
consecutive MS/MS acquisitions. Survey full scan MS spectra (mass range 300-1,800) were 
acquired in the Orbitrap at a resolution of 70,000 at 200 m/z with an automatic gain control 
(AGC) fixed at 3 x 106 ions and a maximal injection time set to 50 ms. The ten most intense 
peptide ions in each survey scan with a charge state ≥ 2 were selected for MS/MS. MS/MS 
spectra were acquired at a resolution of 17,500 at 200 m/z, with a fixed first mass at 100 m/z, 
AGC was set to 1 x 105, and the maximal injection time was set to 100 ms. Peptides were 
fragmented in the HCD cell by higher-energy collisional dissociation with a normalized collision 
energy set to 27. Peaks selected for fragmentation were automatically included in a dynamic 
exclusion list for 60 s, and peptide match selection was turned on. MS data were saved in RAW 
file format (Thermo Fisher Scientific) using XCalibur. Raw data collected were processed and 
converted with MSConvert in .mgf peak list format. 
 
Raw files were processed using MaxQuant (v1.5.5.1). Peak lists were searched using the decoy 
mode of the Andromeda search engine implemented in MaxQuant against a protein database 
created using MSDA, our home-developed software suite (Carapito et al., 2014). The database 
contained human and bovin protein sequences (UniProtKB-SwissProt Taxonomy ID: 9606 and 
9913 respectively; 26191 entries), which were downloaded in May 2017. Sequences of common 
contaminants like keratins and trypsin (247 entries, included in MaxQuant) were finally added to 
the protein database. Regarding search parameters, MS tolerance was set to 20 ppm for the first 
search and 4.5 ppm for the main search. A maximum number of 2 missed cleavage was accepted, 
and carbamidomethylation of cysteine residues was set as fixed modification, while acetylation 
of protein N-termini and oxidation of methionine residues were set as variable modifications. 
False discovery rates (FDR) were set to 1% for both peptide spectrum matches (minimum length 
of 7 amino acids) and proteins. Finally, based on the principle of parsimony, shared peptides 
between proteins were attributed to the protein with the highest number of assigned peptides.  
Regarding quantification, data normalisation and estimation of protein abundance was performed 
using the MaxLFQ (label free quantification) option implemented in MaxQuant (Cox et al., 
2014). “Match between runs” was enabled using 0.7 minutes time windows after retention time 
alignment. MaxLFQ quantification was applied using a minimal ratio count of one. Both 
unmodified and modified (acetylation of protein N-termini and oxidation of methionine residues) 
peptides were considered for quantification, but shared peptides were not. All other MaxQuant 
parameters were set as default. The MaxQuant results were visualized and treated with Prostar 
software for statistical analysis (Wieczarek et al., 2017). Only proteins with at least three 
intensity values in at least one of the two groups to be compared were retained. Welch’s t-test 
was applied to identify differentially expressed proteins at a p-value <0.05.  
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Western blotting 
SVG-A cells were lysed in a buffer containing 50 mM Tris-HCl (pH 7.5), 0.3 M NaCl, 0.5% 
Triton X-100, and protease inhibitors (1x, Roche) for 20 min on ice, with intense vortexing at the 
begging and end of the incubation. Lysates were cleared by centrifugation at 18000xg for 15 min 
at 4oC before transferring the supernatant to new tubes. The protein content in the lysates and in 
the purified EV fractions was measured in the presence of 0.2% SDS, using Pierce BCA protein 
assay kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. For each WB, 
20 μg of lysates or 3 μg of EV pellets were loaded on 4-12% NuPAGE Bis-Tris Protein Gels 
(Invitrogen) and ran under non-reducing conditions. Transfer was done using iBlot2 NC Transfer 
stacks (Invitrogen) prior to primary antibody incubation overnight at 4oC. Membranes were 
revealed by chemiluminescence using Clarity or Clarity Max Western ECL Blotting Substrates 
(Bio-Rad) and images were acquired using ChemiDoc Touch system (Bio-Rad).  
 
Immunostaining and Time-lapse microscopy 
SVG-A cells were grown on glass coverslips in 24-well plates for 24 h, prior to transfection with 
a plasmid encoding for mNeonGreen-Shh using JetPrime according to the manufacturer’s 
instructions. 24 h later, cells were washed once with PBS and fixed for 20 min at room 
temperature (RT) with 4% paraformaldehyde. Blocking and permeabilization was done with 
PBS-0.1% Triton X-100 and 0.5% BSA for 30 min. Cells were incubated with the indicated 
primary antibodies for 2 h at RT, followed by incubation with secondary antibodies for 45 min, 
diluted in blocking buffer (Alexa Fluor Donkey anti-Mouse-647 or Alexa Fluor Donkey anti-
Rabbit-647). Coverslips were mounted with Fluoromount (Sigma-Aldrich). Image acquisition 
was performed using an AxioObserver.Z1 inverted microscope (Zeiss) mounted with a spinning 
disc head (Yokogawa), a back-illuminated EMCCD camera (Evolve, Photometrics) and a X100, 
1.45 NA oil objective (Zeiss) controlled by Visiview v.3.3.0 software (Visitron Systems). For 
live cell imaging, cells were co-transfected as described above with mNG-SHH and TagRFP-
CHMP1A on coverslips in 6-well plates, and imaged 48h later in cell media at 37oC and 5% CO2 
in a dark incubation chamber. Z-stacks of 0.5 µm interval with two-channel detection were 
acquired every 5 s, and time-lapse images were analyzed with Imaris v.9.0.1 (Bitplane). 
 
SHH signaling and RT-qPCR 
NIH3T3 cells were seeded in 48-well plates to confluency and cultured for 24 h in complete 
DMEM. Cells were then grown in media without FBS for another 24h, prior to incubation for 
another 48 hours with the indicated amounts of SHH-containing 100K vesicles or mock (PBS). 
As positive control of pathway activation, cells were incubated with 250nM SAG reconstituted 
in DMSO (Abcam) or DMSO as control. Total RNA was isolated using ReliaPrep RNA Cell 
Miniprep System (Promega) and cDNA was created with SuperScript VILO Master Mix 
(Invitrogen) by manufacturer’s instructions. qRT-PCR assay was run on the CFX96 Touch Real-
Time PCR Detection System and gene expression was measured with primers specific for the 
SHH downstream target gene GLI1 (F: TTGGATTGAACATGGCGTCT and R: 
CCTTTCTTGAGGTTGGGATGA). Gene expression is shown as fold change relative to mock-
treated cells, following normalization to housekeeping gene RPL27 (F: 
GTCGAGATGGGCAAGTTCAT and R: GCTTGGCGATCTTCTTCTTG). 
 
Cytokinesis analysis 
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Mouse cortex at E14.5 and cultured iPSCs were fixed in 4% PFA.  Cortical ventricular surface or 
cultured iPSCs were immunostained with antibodies against aurora A kinase, pH3 and Hoechst.  
Aurora A labels the midbody in anaphase through telophase while pH3 labels histones from 
prophase through metaphase.  A high-power field was imaged and the number of pH3 positive 
early mitotic cells and the number of aurora A positive late mitotic cells was counted.  The ratio 
of midbodies to pH3 positive cells was calculated as measure of cytokinesis duration. 
 
Electron microscopy  
Embryonic mouse choroid plexus and P0 mouse cerebellum was fixed in 2.5% Glutaraldehyde 
and 2% Paraformaldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) at 4C overnight.  70 um 
thick tissue sections were cut on a vibratome.  Sections were washed in 0.1 M cacodylate buffer 
and postfixed with 1% Osmiumtetroxide (OsO4) and 1.5% Potassiumferrocyanide (KFeCN6) for 
1 hour, washed in water 3x and incubated in 1% aqueous uranyl acetate for 1 hour followed by 2 
washes in water and subsequent dehydration in grades of alcohol (10 min each; 50%, 70%, 90%, 
2x 10 min 100%).  The samples were then infiltrated for 15 min in a 1:1 mixture of 
propyleneoxide and TAAB Epon (Marivac Canada Inc. St. Laurent, Canada). The samples were 
embedded in drops of TAAB Epon between two sheets of aclar plastic (Electron Microscopy 
Sciences) and polymerized at 60C for 48 hours.  Ultrathin sections (about 80 nm) were cut on a 
Reichert Ultracut-S microtome, placed onto copper grids, stained with uranyl acetate and lead 
citrate and examined in a JEOL 1200EX transmission electron microscope.  Images were 
recorded with an AMT 2k CCD camera. 
 
SEM samples were postfixed in 1.0% osmium tetroxide in 0.1M cacodylate buffer (pH 7.4) for 1 
hour at room temperature.  Following postfixation, the samples were rinsed with buffer then 
dehydrated through a graded series of ethanol.  The specimens were then critical point dried with 
CO2 using a Samdri PVT-3 critical point dryer (Tousimis Corp.  Rockville, MD).  The 
specimens were attached to specimen mounts using conductive adhesive tabs, coated with 5nm 
platinum using a Cressington 208HR sputter coater (Cressington Scientific Instruments, Ltd. 
Walford, UK). SEM images were collected on a Hitachi S-4800 at Northeastern University. 
 
For FIB-SEM, Durcupan embedded sample was first mounted on a Cu stud, then imaged by a 
customized Zeiss NVision40 FIB-SEM system previously described (Xu, et al., 2017). The 
sample was biased at 400 V to improve image contrast by filtering out secondary electrons. The 
block face was imaged by a 1 nA electron beam with 1.5 keV landing energy at 500 kHz. The x-
y pixel resolution was set at 8 nm. A subsequently applied focused Ga+ beam of 27 nA at 30 keV 
strafed across the top surface and ablated away 2 nm of the surface. The newly exposed surface 
was then imaged again. The ablation – imaging cycle continued about once every minute for 
couple days. The sequence of acquired images formed a raw imaged volume, followed by post 
processing of image registration and alignment using a Scale Invariant Feature Transform (SIFT) 
based algorithm. The aligned stack was binned by a factor of 4 along z to form a final isotropic 
volume of 28x34x5 µm3 with 8x8x8 nm3 voxels, which can be viewed in arbitrary orientations. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
In all analyses, mean values are presented for pooled data and errors bars are SEM. 
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Relative intensities of the WB bands were quantified using ImageLab software version 5.2.1 
(Bio-Rad) using Volume Tools, global background subtraction and linear regression method. 
Band intensities of WT samples were set as 100% and used to calculate the protein levels in the 
KO samples, plotted as percentage of WT (Figures 6E, 6F).  
 
For mass-spec experiments, Welch’s t-test was applied to identify differentially expressed 
proteins at a p-value <0.05 (Figure 7E, Table 2). 
 
For RNA-sequencing of cerebral organoids, the significance of gene expression differences was 
calculated with the DESeq2 adjusted p-value. For GO pathway analysis, each Functional 
Annotation Cluster, the benjamini-corrected p-value for the highest-ranking individual GO-term 
in each cluster is displayed next to the bar graphs. For comparison between organoid gene 
expression and human developing cortex, pairwise calculation of Spearman’s rank correlation 
was done for each comparison. 
 
For all other quantifications, statistical significance was determined using a two-tailed, unpaired 
t-test or a Mann-Whitney test. All counts of ILVs per MVB failed the D’Agostino and Pearson 
normality test (p < 0.01). As a result, the nonparametric Mann-Whitney test was used to test 
significance of ILV per MVB differences. Statistical analyses were performed using GraphPad 
Prism version 7. 
 
DATA AND SOFTWARE AVAILABILITY 
RNA sequencing data will be deposited in GEO. 
Proteomics data have been deposited in ProteomeXchange (PXD007990). 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rat anti L1CAM Millipore  MAB5272 
Mouse anti TUJ1 Biolegend  801201 
Rabbit anti CHMP1A (WB) Stan Hollenberg  
Rabbit anti CHMP1A (IHC) ProteinTech  15761-1-AP 
Mouse anti Beta actin Abcam  AC-15 
Mouse anti Calbindin Abcam  AF2E5 
Mouse anti AQP1 Santa Cruz  SC25287 
Rat anti CTIP2 Abcam  AB18465 
Goat anti SOX2 Santa Cruz  SC17330 
Mouse anti CD63 Pelicluster  M1544 
Rabbit anti CUX1 Santa Cruz  SC13024 M-222 
Rat anti phospho Histone H3 Sigma  H9908 
Rabbit anti SHH Abcam  AB73958 
Rabbit anti Cleaved caspase 3 Abcam  AB13847 
Mouse anti Beta catenin BD  610153 
Rabbit anti Atypical PKC Santa Cruz  SC216 
Mouse anti Aurora A BD  611082 
Mouse anti CD9 Millipore CBL162 
Rabbit anti CD9 Abcam ab92726 
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Mouse anti CD81 Santa Cruz sc-166029 
Mouse anti CD81 Abcam ab59477 
Mouse anti TSG101 Abcam ab83 
Mouse anti TSG101 Thermo Fisher  MA1-23296 
Rabbit anti Syntenin Abcam ab133267 
Rat anti GP96 Enzo Life Sciences ADI-SPA-850-F 
Rabbit anti AXL Cell Signaling  8661S 
Rabbit anti RAB18 MilliporeSigma SAB4200173 
Rabit anti TMED10 Sigma-Aldrich HPA047139 
Goat anti SHH Santa Cruz sc-1194 
Rabbit anti PAX6 Covance  PRB-278P-100 
Bacterial and Virus Strains  
None   
Biological Samples   
Human CSF Eric Wong  
Human choroid plexus Hart Lidov  
Chemicals, Peptides, and Recombinant Proteins 
Smoothened agonist (SAG) Abcam ab142160 
Critical Commercial Assays 
Dynabeads Antibody Coupling Kit Invitrogen 14311D 
RNAscope ACDBio  
Shh ELISA R&D Systems MSHH00 
Deposited Data 
RNA sequencing GEO  
Proteomics ProteomeXchange PXD007990 
Experimental Models: Cell Lines 
SVG-A T Kirchhausen  
iPSC (IMR90) WiCell  
NIH3T3 ATCC  
Chmp1a null MEF This paper  
Experimental Models: Organisms/Strains 
Chmp1a gene trap mouse This paper  
Ptch mutant mouse JAX  
Oligonucleotides 
CHMP1A gRNA This paper  
Luciferase gRNA This paper  
Gli1 qPCR F primer This paper  
Gli1 qPCR R primer This paper  
Rpl27 qPCR F primer This paper  
Rpl27 qPCR R primer This paper  
Chmp1a WT F primer This paper  
Chmp1a GT F primer This paper  
Chmp1a WT R primer This paper  
Chmp1a GT R primer This paper  
Recombinant DNA 
Mouse Ptch in situ probe Constance Cepko  
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mNG-SHH  Corey Harwell  
TagRFP-CHMP1A This paper  
Cas9 GFP Kirin Musunuru  
Cas9-E2-Crimson Feng Zhang  
gRNA backbone Kirin Musunuru  
RNAscope probe Hs CD63 ACDBio 505901 
RNAscope probe Hs SHH ACDBio 600951 
RNAscope probe Hs PTCH ACDBio 422161 
RNAscope probe Hs CHMP1A ACDBio 505911 
Software and Algorithms 
Visiview Visitron Systems  
Imaris Bitplane  
ImageLab Bio-Rad  
CFX Manager Bio-Rad  
ImageJ NIH  
XCalibur Thermo  
MSConver   
MaxQuant   
Prostar   
Prism 7 GraphPad  
Other 
None   
 
Supplemental Movie 1: Live-cell imaging showing partial co-distribution of intracellular 
CHMP1A and SHH signal over time 
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Supplemental Figure 1: Chmp1a gene trap mouse model 
 
(A) Model of gene trap cassette in mouse Chmp1a locus. (B) Western blot shows Chmp1a null 
mice express no Chmp1a protein. (C) Sanger sequencing of genomic DNA in Chmp1a null mice 
shows fusion of Chmp1a intron 1 to En2 intron 1 in GT cassette. (D) Mendelian ratios of 
Chmp1a GT litters during embryonic development. Expected Mendelian ratio is shown in the left 
bar. At late embryogenesis, Chmp1a gt/gt begin to die and few are recovered at P0. (E) Chmp1a 
+/gt embryos do not have a defect in embryonic development compared to Chmp1a +/+ 
embryos. Mass and p-values of +/+ vs +/gt are shown below, two-tailed t-test. (F) Chmp1a +/gt 
embryos do not have a defect in embryonic brain development compared to Chmp1a +/+ 
embryos. Mass and p-values of +/+ vs +/gt are shown below, two-tailed t-test. (G) Chmp1a null 
mouse telencephalon and olfactory bulb are hypomorphic. 
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Supplemental Figure 2: MRI imaging of patients with CHMP1A null mutations  
 
(A) MRI images of one control and two patients with CHMP1A null mutations. Control is a 
neurologically normal 2 year old male, CH-2701 is 6 month old female with Q30X CHMP1A 
mutation, and CH-3105 is 3 month old male with c.28-13G>A V33fs CHMP1A mutation 
(Mochida et al., 2012). Sagittal images show decreased head circumference (microcephaly) and 
severe cerebellar hypoplasia (arrowhead) in absence of CHMP1A. Coronal images show 
hypoplasia of caudate (arrowheads) in absence of CHMP1A. 
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Supplemental Figure 3: CHMP1A RNAscope, ChP expression, and expression controls 
 
(A) Chmp1a immunoreactivity is punctate in epithelial cells of hindbrain choroid plexus at P0. 
AQP1 labels ventricular surface. (B) CHMP1A, SHH, and CD63 expression in developing 
human cortex by RNAscope. (C) Beta-gal staining in wild type mouse shows no signal in 
cerebellum or choroid plexus at P4. (D) Immunostain for Chmp1a shows no signal in Chmp1a 
null cerebellum at P0. All panels are representative image of ≥2 experiments. 
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Supplemental Figure 4: Developing cortex and cerebellum in Chmp1a null mouse 
 
(A) Purkinje cell layer is intact in Chmp1a null P0 pups and unchanged compared to littermate 
controls. Immunostain for Calbindin labels Purkinje cells in control and Chmp1a null P0 
cerebellum. (B) Fraction of cerebellum area covered by the Purkinje cell has no detectable 
difference in Chmp1a null pups compared to controls (Control: n=4, Chmp1a null: n=2, two-
tailed t-test, p = 0.16). (C) During cortical development, there is no detectable increase in 
apoptosis in Chmp1a null embryos compared to controls. Apoptotic cells in developing cortex 
(E12.5) were labeled with immunostaining for cleaved caspase 3. (D) Quantification of (A), 
Control: n=6, Chmp1a null: n=3, two-tailed t-test, p = 0.52. (E) There is no detectable defect in 
cortical ventricular surface formation in Chmp1a null embryos. Immunostaining for beta-catenin 
and atypical protein kinase C, two proteins that localizes at the ventricular surface, showed no 
focal defects in ventricular surface or changes in protein distribution in Chmp1a null developing 
cortex (E14.5). Representative image of 2 experiments. (F) SHH drives GCP proliferation more 
in anterior lobe than in dorsal lobe. (G) Control littermates have 75% more mitotic GCPs in the 
anterior lobe compared to the dorsal lobe; in contrast, Chmp1a null pups have only 25% more 
mitotic GCPs in anterior lobe, Control: n=7, Chmp1a null: n=4, two-tailed t-test, p = 0.005. Two-
tailed, unpaired t-test, * p < 0.05, ** p < 0.01. 
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Supplemental Figure 5: Chmp1a is not required for cytokinesis 
 
(A) Cytokinesis disruption was not detected in the absence of CHMP1A. Ventricular surface of 
mouse cortex and cultured iPSCs were immunostained for pH3 and aurora A (images show 
mouse cortex ventricular surface). pH3 labels early mitotic cells and aurora A labels the midbody 
of late mitotic cells. The fraction of mitotic cells in cytokinesis was calculated as: (Aurora A) / 
(Aurora A + pH3). (B) There was no detectable difference in the fraction of cells in cytokinesis 
in ventricular cortical progenitors of Chmp1a null embryos compared to littermate controls 
(Control: n=8, Chmp1a null: n=7, two-tailed t-test, p = 0.093). (C) There was no detectable 
difference in fraction of cells in cytokinesis in CHMP1A null and WT cultured iPSCs (Control: 
n=15, Chmp1a null: n=15, two-tailed t-test, p = 0.59). (D) Propidium iodide staining of Chmp1a 
null and control MEF lines. There was no detectable difference in distribution of DNA content 
between Chmp1a null (n=1) and control MEFs (n=2).  
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Supplemental Figure 6: Chmp1a null ; Ptch mutant mouse and Gli1 in MEFs 
 
(A) Brain weight of Chmp1a null ; Ptch heterozygous mouse embryos at E18.5/P0 (Control: 
n=25, Ptch het: n=10, Chmp1a null: n=4, Chmp1a null ; Ptch het: n=5, two-tailed t-test, Ptch 
het: p < 0.001, Chmp1a null: p < 0.001, Chmp1a null ; Ptch het: p = 0.22). (B) Shh signaling is 
intact in Chmp1a null MEFs. MEFs were stimulated with SAG and Gli1 expression increase was 
used to measure Shh pathway activation.  There is no detectable difference between Chmp1a null 
and littermate control MEFs (Control: n=4, Chmp1a null: n=4, two-tailed t-test, p = 0.39). Two-
tailed, unpaired t-test, ** p < 0.001.  
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Supplemental Figure 7: Human organoid RNA sequencing quality control metrics 
 
(A) Sanger sequencing showing wild type and 1 bp frameshift deletion and resulting premature 
STOP codon in CHMP1A null iPSC line (fsV33X). CHMP1A null iPSCs do not express 
CHMP1A protein. (B) MA plots of pairwise comparisons of organoid RNA-sequencing data.  
Data shows output values of DESeq2 analysis, Y-axis shows DESeq2 corrected Log2 fold-
change, X-axis basemean expression levels. Colored dots represent genes according to their p-
value. (C) PCA plot of all samples and replicates used in this study after normalization using 
DESeq2. 
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Supplemental Figure 8: Gene expression changes following SAG treatment of human 
organoids 
 
(A) Comparison of d38 organoid data to Brainspan data using Spearman’s rank correlation. 
Highlighted in red shows SAG treatment of control organoids increases correlation with w9 and 
more strongly with w8 DFC data compared to DMSO treated control organoids. CHMP1A null 
organoids respond as well but to a lesser extent. (B) Comparison of d38 organoid data to d14 
organoid data. Similarly to panel A, SAG treated control organoids show better correlation with 
early stage day14 organoids. (C) GO analysis of differentially expressed genes. SAG treatment 
leads to upregulation of proliferation genes and downregulation of differentiation genes in both 
control and CHMP1A null cerebral organoids (light grey bars). There are also genes regulated 
only in control or only in CHMP1A null organoids, which were analyzed as separate groups 
(dark grey bars, black bars respectively). Control organoids show extra sets of genes positively 
regulating cell cycle, and negatively regulating differentiation. (D), (E), (F) Representative genes 
and their expression changes from analyses and groups shown in panels A, B and C.   
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Supplemental Figure 9: Choroid plexus epithelial surface and additional MVBs 
 
(A) Partial colocalization of CHMP1A and CD63 puncta (inset and arrowheads) at the 
ventricular surface of human hindbrain ChP (11 d.o.). Representative image of 2 experiments. 
(B) There is no detectable defect in choroid plexus epithelial cell microvilli in Chmp1a null 
embryos at E17.5. (C) Additional examples of choroid plexus epithelial cell MVBs in control 
and Chmp1a null littermates. Chmp1a null MVBs contain fewer ILVs and often contain large 
ILVs. (D) Additional examples of Purkinje cell MVBs from Chmp1a null P0 pups and littermate 
controls. Chmp1a null MVBs contain fewer ILVs than controls. 
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Supplemental Figure 10: MVBs localize to dendrites in postmitotic neurons 
 
(A) MVBs are in distal (2) and proximal (3) Purkinje cell dendrites in developing cerebellum at 
P4. (B) MVBs are located in Purkinje cell dendrites at P0. (C) MVBs in dendrites of layer II/III 
cortical pyramidal neurons. High magnification image shows a MVB (white arrowhead) near an 
excitatory synapse in a pyramidal cell dendritic spine and near an inhibitory synapse in a 
dendritic shaft. MVBs locations are represented by red dots in a rendered 3D TEM 
reconstruction of a serially sectioned pyramidal neuron.  
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Supplemental Figure 11: CHMP1A null SVG-A cell lines 
 
(A) CHMP1A null SVG-A cell line Sanger sequencing shows a 5 bp frameshift deletion in exon 
3. This mutation creates a stop codon after exon 3. (B) No CHMP1A protein is detected by 
immunoblot in CHMP1A null SVG-A cells. (C) 100K EV fraction purified from pooled SVG-A 
cells transfected with CHMP1A null gRNA and Cas9. As we found in a stable monoclonal 
CHMP1A null SGV-A line, secretion of exosomal markers and SHH is decreased. 
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Supplemental Figure 12: CHMP1A is associated with ART-EV complexes and partially co-
distributes with intracellular SHH 
 
(A) SHH-positive vesicles from the 100K pellet of WT and CHMP1A null SVGA cells were 
immunoisolated (right panel) using different input amounts (left panel), so that the SHH levels in 
the WT and KO input fractions are equivalent. WB analysis of the bound material shows 
CHMP1A in SHH-EVs from WT but not KO cells, while RAB18 and AXL are present in both 
fractions. (B) SVG-A cells were transfected with TagRFP-CHMP1A and mNG-SHH expressing 
plasmids and 48 h later, 15 z stacks of 0.5 µm were acquired every 5 seconds on a spinning disk 
confocal microscope using 488 and 561 nm lasers lines and associated filter sets. Snapshots 
show a z projection for each channel and the color-coded merge (upper panels). Cropped images 
(lower panels) show a single z plane, and the arrowhead points at colocalizing CHMP1A and 
SHH signals. Scale bar is 10 µm. See full video in Supplemental Movie 1. 
